Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD4076 in T2DM with NAFLD
NCT02826525Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Jul 2016
- Primary completion
- Oct 2019
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
01
Overview
Phase 1, randomised, single-blind trial of RG-125 in type 2 diabetes mellitus (T2DM) and non-alcoholic fatty liver disease (NAFLD) (2 arms), sponsored by AstraZeneca. Primary endpoints: Number of participants with adverse events at 26 weeks, Blood pressure at 26 weeks and 11 more. Started Jul 2016; status: completed.
02
Drugs
RG-125
03
Conditions
type 2 diabetes mellitus (T2DM)non-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT02826525.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02826525.